Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19 : Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19: a Single-center, Observational Retrospective-prospective Comparative Study.
This is a Pilot study for evaluating the feasibility, security and efficacy of the use of Cypropheptadine, an antihistaminic and antiserotonin drug, as an adjunct of the standardized treatment in a population of patient who are hospitalized and requiring oxygen therapy for COVID-19..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ClinicalTrials.gov - (2021) vom: 06. Mai Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: May 6, 2021, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
|---|
| Study ID: |
NCT04876573 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG00746794X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG00746794X | ||
| 003 | DE-627 | ||
| 005 | 20230425202631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210510s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG00746794X | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04876573 | ||
| 035 | |a (UBBS_Klinische_Studien)2022-2669 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19 |b Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19: a Single-center, Observational Retrospective-prospective Comparative Study. |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: May 6, 2021, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
| 520 | |a This is a Pilot study for evaluating the feasibility, security and efficacy of the use of Cypropheptadine, an antihistaminic and antiserotonin drug, as an adjunct of the standardized treatment in a population of patient who are hospitalized and requiring oxygen therapy for COVID-19. | ||
| 650 | 2 | |a Pneumonia, Viral | |
| 650 | 2 | |a Malignant Carcinoid Syndrome | |
| 650 | 2 | |a Pneumonia | |
| 650 | 2 | |a Serotonin Syndrome | |
| 650 | 4 | |a Medical Condition: Viral Pneumonia, COVID-19 Pneumonia, Serotonin Syndrome, Platelet Dysfunction | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Not yet recruiting | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 06. Mai |
| 773 | 1 | 8 | |g year:2021 |g day:06 |g month:05 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04876573 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 06 |c 05 | ||